Barclays PLC purchased a new position in shares of Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 247,575 shares of the company’s stock, valued at approximately $169,000. Barclays PLC owned approximately 2.66% of Lakeshore Biopharma at the end of the most recent reporting period.
Separately, FMR LLC bought a new stake in shares of Lakeshore Biopharma in the 3rd quarter valued at about $803,000. Hedge funds and other institutional investors own 52.64% of the company’s stock.
Lakeshore Biopharma Trading Up 1.6 %
Shares of LSB opened at $2.55 on Thursday. Lakeshore Biopharma Co., Ltd. has a 52 week low of $1.88 and a 52 week high of $11.20. The firm has a 50-day moving average of $2.87. The company has a current ratio of 1.17, a quick ratio of 0.90 and a debt-to-equity ratio of 0.13.
About Lakeshore Biopharma
LakeShore Biopharma Co, Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People’s Republic of China and Other Countries or Regions.
Featured Articles
- Five stocks we like better than Lakeshore Biopharma
- When to Sell a Stock for Profit or Loss
- Oracle Announces Game-Changing News for the AI Industry
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- Investing In Preferred Stock vs. Common Stock
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Lakeshore Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakeshore Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
